Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1201-1220 of 1,738 trials

Multiple Myeloma: Isatuximab with Evorpacept and Dexamethasone

We are studying a new treatment combination for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if it improves treatment responses compared to existing options.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Nephrogenic Diabetes Insipidus: Amiloride Treatment Study

We are investigating whether amiloride can help patients with nephrogenic diabetes insipidus caused by lithium treatment for bipolar disorder. The study looks at its effects on urine concentration, thirst, and quality of life.

Bipolar Disorder with Lithium Treatment>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNephrologyPsychiatry

Advanced Cancers: New Treatment Study

We are exploring a new treatment option for patients with advanced cancers. This study aims to see if it can improve outcomes compared to standard care.

Advanced Solid TumourSafety phase (I)Efficacy phase (II)Oncology

Chronic Cough: Taplucainium Inhalation Powder

We are studying a new inhalation powder for adults with chronic cough that hasn't improved with other treatments. The trial will evaluate its effects on cough frequency and quality of life compared to a placebo.

Refractory or Unexplained Chronic Cough3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Blood Cancers: AZD0486 Treatment Study

We are investigating whether AZD0486, alone or with other cancer drugs, is safe and effective for adults with certain blood cancers. This includes conditions like chronic lymphocytic leukemia and large B-cell lymphoma.

Mantle Cell LymphomaLarge B-Cell LymphomaChronic Lymphocytic LeukaemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Right Heart Failure: Dapagliflozin Study

We are investigating whether adding dapagliflozin to standard care helps patients with chronic right heart failure more than standard care alone. This study aims to improve treatment options for these patients.

Chronic Right Heart Failure6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Prostate Cancer: Apalutamide with Surgery

We are studying if adding apalutamide to standard hormone therapy helps men with high-risk prostate cancer after surgery. The goal is to see if this combination improves cancer control compared to hormone therapy alone.

Metastatic Prostate Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Primary Plasma Cell Leukemia: ARI0002h CAR-T Cell Therapy

We are studying a new CAR-T cell treatment for patients newly diagnosed with primary plasma cell leukemia. The trial aims to evaluate its safety, effectiveness, and impact on quality of life.

Plasma Cell Leukaemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Hodgkin Lymphoma: Chemotherapy Alone Study

We are exploring whether chemotherapy alone is effective for patients with early-stage Hodgkin Lymphoma who have a good prognosis. This study aims to improve treatment options and monitor for potential relapses.

Classical Hodgkin LymphomaEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Hodgkin's Lymphoma: Nivolumab and Chemotherapy Study

We are studying a new treatment approach using nivolumab followed by chemotherapy for patients with Hodgkin's lymphoma that hasn't responded to previous therapy. The goal is to see if this combination improves treatment outcomes and safety.

Refractory Hodgkin LymphomaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Breast Cancer: Nivolumab and Novel Immunotherapies

We are studying whether nivolumab, alone or with other treatments, can help achieve a complete response in early breast cancer patients before surgery. This trial also looks at safety and how well the treatment works.

Breast Cancer≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Breast Cancer Treatment: I-BCT-1 Study

We are exploring how genetic changes in breast tumors can help select the best treatment options for patients. This study includes patients with neoadjuvant and metastatic breast cancer to improve therapy outcomes.

Breast Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Type 1 Diabetes: Verapamil Treatment for Children

We are studying whether oral Verapamil can help preserve insulin production in children recently diagnosed with Type 1 diabetes. The trial also looks at the safety and effectiveness of this treatment in managing blood sugar levels.

Type 1 Diabetes>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsStandard MedicinesDiabetologyEndocrinology

Solid Tumors: Genetically Modified T-Cell Therapy

We are studying a new treatment using modified T-cells from patients to target specific tumor markers in solid tumors. The trial will help us understand its safety and effectiveness, both alone and with another medication.

Solid TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Liver Cancer: Immunotherapy and Radioactive Treatment Study

We are studying the effects of two immunotherapy drugs combined with a special treatment for liver cancer. This trial aims to see if this combination improves survival and quality of life for patients with non-resectable liver cancer.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyOncology

Advanced Breast Cancer: The p53 Trial

We are testing a chemotherapy treatment for patients with advanced breast cancer that has TP53 mutations. The goal is to see how well it works and to understand the safety and response of different mutation types.

Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Recurrent Grade-4 Glioma: Bortezomib and Temozolomide Study

We are studying the safety and effectiveness of combining Bortezomib with Temozolomide for patients with recurrent grade-4 glioma. This research may help improve treatment options for this challenging condition.

Malignant Glioma3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Short Bowel Syndrome: HM15912 Treatment Study

We are testing HM15912 to see if it is safe and well-tolerated in adults with Short Bowel Syndrome. This study will help us understand how the treatment works in the body.

Short Bowel Syndrome1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteGastroenterologyInternal Medicine

CAR T-Cell Therapy for Blood Cancers

We are testing a new CAR T-cell treatment for patients with relapsed or refractory CD19-positive blood cancers. The study aims to evaluate its safety and effectiveness compared to existing therapies.

Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Hepatocellular Carcinoma: 68Ga-PSMA PET Imaging Study

We are evaluating a new imaging method to see if it can better detect recurrence of liver cancer in patients who have been treated before. This study aims to improve monitoring and treatment strategies for these patients.

Liver Cancer1-2 yearsSafety phase (I)Efficacy phase (II)HepatologyOncology